Abstract: Compounds of the formula ##STR1## wherein Z is ##STR2## proline, pipecolic acid, an indolecarboxylic acid or an isoquinolinecarboxylic acid. These compounds are useful as cardiovascular agents.
Type:
Grant
Filed:
March 26, 1993
Date of Patent:
May 9, 1995
Assignee:
E. R. Squibb & Sons, Inc.
Inventors:
Norma G. Delaney, George C. Rovnyak, Melanie J. Loots
Abstract: An enantiomerically pure compound of the formula ##STR1## is prepared when the associated racemic mixture is reacted with an acrylating agent R.sup.3 --C(O)--O--R in the presence of a microorganism or enzyme derived therefrom capable of catalyzing transesterification of an alcohol. X.sup.1 and X.sup.2 are each independently halogen, R is alkyl, R.sup.1 and R.sup.2 are each independently alkyl, cycloalkyl, aralkyl or aryl and R.sup.3 is alkyl, cycloalkyl, aryl or aralkyl.
Type:
Grant
Filed:
March 24, 1993
Date of Patent:
May 9, 1995
Assignee:
E. R. Squibb & Sons, Inc.
Inventors:
Ramesh N. Patel, Clyde G. McNamee, Laszlo J. Szarka
Abstract: The protected cyclobutanone of the formula ##STR1## is treated with a dialkylaluminum chloride, an alkylaluminum dichloride, a trialkylaluminum compound, diphenylsilane in the presence of tris(triphenylphosphine) rhodium (I) chloride, or iridium tetrachloride to yield the corresponding diprotected cyclobutanol. This compound is useful as an intermediate in the preparation of antiviral agents.
Type:
Grant
Filed:
May 26, 1992
Date of Patent:
May 2, 1995
Assignee:
E. R. Squibb & Sons, Inc.
Inventors:
Janak Singh, Gregory S. Bisacchi, Richard H. Mueller
Abstract: A retractile penis device comprises an apertured plate carrying an inflatable toroid ring, the ring being substantially aligned with the aperture and acting in use when inflated to apply pressure to the base of the penis and the surrounding skin area of the wearer.
Abstract: Isolated nucleic acid molecules capable of hybridizing to sequences of Candida albicans along with methods utilizing such probes for the detection of Candida albicans in clinical and other biological samples.
Type:
Grant
Filed:
December 17, 1991
Date of Patent:
April 11, 1995
Assignee:
E. R. Squibb & Sons, Inc.
Inventors:
Jessica A. Gorman, Catherine A. Bingham
Abstract: Novel indane and quinoline derivatives, useful, for example, as antiischemic agents, having the formula ##STR1## where A, X, R.sub.1 -R.sub.7 are as defined herein, are disclosed.
Abstract: A process is described for selectively preparing a compound of the formula ##STR1## wherein: R.sup.1 is halogen;R.sup.2 is halogen, alkyl, cycloalkyl, aryl or ##STR2## and R.sup.3 hydrogen, alkyl, cycloalkyl, aryl, ##STR3## wherein the process comprises treating the associated ketone with an oxido-reductase or a microorganism comprising an oxidoreductase. Compounds prepared by this process are useful antipsychotic agents or useful intermediates therefor.
Type:
Grant
Filed:
April 14, 1993
Date of Patent:
February 28, 1995
Assignee:
E. R. Squibb & Sons, Inc.
Inventors:
Ramesh N. Patel, Mark Liu, Amit Banerjee, Laszlo J. Szarka
Abstract: Angiotensin II inhibition is exhibited by ##STR1## wherein: X is --CH.sub.2 -- or O;R is hydrogen, alkyl, aryl, cycloalkyl, aralkyl, or cycloalkylalkyl;R.sup.1 and R.sup.2 are each independently O or absent;R.sup.3 is hydrogen, alkyl, alkenyl, alkoxy, cycloalkyl, aryl, aralkyl, cycloalkylalkyl, halo, haloalkyl, or haloalkoxy;R.sup.4 is hydrogen, alkyl, alkenyl, alkoxy, aryl, cycloalkyl, aralkyl, cycloalkylalkyl, --R.sup.8 --OH, or --R.sup.8 CO.sub.2 R.sup.9 ;and the remaining symbols are as defined in the specification.
Abstract: The ostomy pouch has a coupling member that can be removed from the pouch envelope to permit flush disposal of the envelope without the coupling member. Flushability of the pouch is further enhanced by forming the pouch with converging side walls. Thus when the pouch is deposited in a toilet bottom end first in a carrier sleeve, the pouch can flow in streamlined fashion through the passages of a toilet and any sewer pipe or septic line connected to the toilet. Depending upon the flush capacity of the toilet and the flow rate of water through the toilet and sewer line, the ostomy pouch can be deposited in the toilet without a carrier sleeve.
Abstract: Novel compounds having the formula ##STR1## wherein R.sub.1, R.sub.2, X and Y are as defined herein. These compounds inhibit the action of angiotensin II and are useful, therefore, for example, as antihypertensive agents.
Abstract: Phosphonic acid squalene synthetase inhibitors are provided which are effective in lowering serum cholesterol and have the formula ##STR1## wherein m is 0 to 3, n is 1 to 5, Y.sup.1 and Y.sup.2 are H or halogen, R.sup.2, R.sup.3 and R.sup.4 are H, metal ion, C.sub.1 to C.sub.8 alkyl, C.sub.3 to C.sub.12 alkenyl, or prodrug ester, and R.sup.1 is a substituted or unsubstituted heteroaryl group or a substituted phenyl group.
Abstract: Novel compounds useful, for example, in the treatment of ischemic conditions and arrhythmia having the formula I ##STR1## wherein X is oxygen, sulfur or --NCN and the R groups are as defined herein.
Abstract: Novel compounds are disclosed having the formula ##STR1## wherein X, R.sub.1, R.sub.2, R.sub.3, R.sub.4, and R.sub.5 are substituents. These compounds inhibit the action of angiotensin II and are useful, therefore, for example, as antihypertensive agents.
Abstract: The ostomy pouch is formed of a flexible plastic material with a waste inlet opening and a gas outlet opening proximate the waste inlet opening. The gas outlet opening is of a configuration and size that resists entry of outside water into the pouch through the gas outlet opening. A filter aligned with the gas outlet opening is bonded at a peripheral zone surrounding the gas outlet opening, leaving an unbonded area that communicates with the gas outlet opening. A free face of the filter is gas impermeable. Gases within the pouch pass through an exposed, gas permeable peripheral edge of the filter toward the center and exit into the unbonded section for evacuation through the gas outlet opening.
Abstract: Antiviral activity is exhibited by compounds having the formula ##STR1## and their pharmaceutically acceptable salts. R.sub.1 is ##STR2## R.sub.2 is hydrogen, --PO.sub.3 H.sub.2, ##STR3## wherein R.sub.3 is hydrogen, alkyl, substituted alkyl, or aryl, and R.sub.4 is alkyl.
Abstract: Novel nitrogen-substituted mevinic acid derivatives which inhibit the activity of HMG-CoA reductase. Pharmaceutical compositions, and methods of use for the treatment or prevention of hypercholesterolemia, atherosclerosis, hyperlipoproteinaemia and hyperlipidemia are provided, as are novel methods for preparation and intermediate compounds.
Type:
Grant
Filed:
October 9, 1992
Date of Patent:
November 29, 1994
Assignee:
E. R. Squibb & Sons, Inc.
Inventors:
Dinos P. Santafianos, Kathleen M. Poss, Eric M. Gordon, Peggy J. McCann
Abstract: A method is provided for inhibiting myocardial cell necrosis and improving myocardial function during myocardial ischemia and/or reperfusion by locally administering to the heart a potent potassium channel activator such as pinacidil or cromakalim.
Abstract: A method of making a gas-permeable liquid-impermeable membrane includes the steps of perforating a film of linear low density polyethylene (or other suitable polyolefin) in such a way as to yield an array of holes each having an average diameter of approximately 350, microns and then solution coating the needled film with a porous polyurethane material having pores of a pore size of 1 to 10 microns.Such a film is advantageously embodied in an ileostomy bag, and is fixed to a bag wall thereof in a location to prevent faecal material contacting the bag filter, by a heat or RF welding operation by which the polyolefin is welded to the bag wall which carries the filter. In use, the polyurethane is exposed to the bag contents, and permits gases to pass but prevents any liquid reaching the filter.
Abstract: Monoclonal antibodies which bind (E)-5-(2-bromovinyl)-arabinofuranosyluracil and/or immunologically related compounds, hybrid cell lines which produce these monoclonal antibodies, and immunoassay methods for detecting (E)-5-(2-bromovinyl)-arabinofuranosyluracil and/or immunologically related compounds using these monoclonal antibodies.
Type:
Grant
Filed:
January 22, 1990
Date of Patent:
October 4, 1994
Assignee:
E. R. Squibb & Sons, Inc.
Inventors:
Edward M. Croze, Jan-I Tu, Marc D. Ogan
Abstract: Novel A-II receptor antagonists have the formula ##STR1## or its isomer ##STR2## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, and R.sub.6, are as defined herein. These compounds inhibit the action of angiotensin II and are useful, therefore, for example, as antihypertensive agents.
Type:
Grant
Filed:
December 16, 1991
Date of Patent:
September 27, 1994
Assignee:
E. R. Squibb & Sons, Inc.
Inventors:
Michael A. Poss, John Lloyd, Karnail S. Atwal